Ratings ANGLE plc

Equities

AGL

GB0034330679

Market Closed - London S.E. 11:35:28 2024-07-12 am EDT 5-day change 1st Jan Change
15.25 GBX +0.99% Intraday chart for ANGLE plc +3.39% +29.79%

Summary

  • From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

  • Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
  • Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • Low profitability weakens the company.
  • The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
  • With an enterprise value anticipated at 6.08 times the sales for the current fiscal year, the company turns out to be overvalued.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • For the last few months, analysts have been revising downwards their earnings forecast.
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.

Ratings chart - Surperformance

Sector: Advanced Medical Equipment & Technology

1st Jan change Capi. Investor Rating ESG Refinitiv
+29.79% 63.89M -
-27.91% 16.33B
A
-56.07% 2.17B
C+
+19.09% 1.88B -
-12.63% 1.45B -
+29.99% 1.32B
B+
+8.32% 853M -
-30.60% 799M -
-36.50% 726M -
C-
+29.48% 622M
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes